BioSpace News Archive

The MagMAX Viral/Pathogen Nucleic Acid Isolation Kit is a new automation-ready kit for scalable recovery of RNA and DNA from viral particles and gram-negative bacteria.

Hutchison China MediTech Limited (“Chi-Med” or “Company”) (AIM/Nasdaq: HCM) today announces that an Extraordinary General Meeting (“EGM”) is to be held at 11:00 a.m. London time on Wednesday, May 29, 2019.

Acacia Pharma Group plc (“Acacia Pharma”), a pharmaceutical company developing and commercialising hospital products for US and international markets, announces that it has received a second Complete Response Letter from the US Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for BARHEMSYS® (amisulpride injection).

DicernaTM Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the submission of an updated investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for DCR-PHXC, the Company’s lead GalXC™ product candidate for the treatment of all forms of primary hyperoxaluria (PH).

Mayfair Diagnostics (Calgary, Canada) has purchased 10 Carestream imaging systems including three CARESTREAM DRX-Evolution/DRX-Evolution Plus digital radiography systems (see video link), two CARESTREAM DRX-Ascend Systems and five CARESTREAM DRX-1 Systems to upgrade their existing medical imaging systems.

The Society for Clinical Research Sites (SCRS) announced that Chris Hoyle, founder and executive director of Elite Research Network, has joined the organization’s Leadership Council.

A recent detailed inspection by the United States Department of Agriculture has again found that Primate Research Organization Alpha Genesis is in full compliance with ALL regulations and standards of the Animal Welfare Act, company officials announced.

Study shows how imipridone drugs ONC201 and ONC212 cause cancer cell death

The Management team of MorphoSys AG will host a conference call and webcast on May 8, 2019 at 2:00pm CEST (1:00pm BST; 8:00am EDT) to present MorphoSys’s first quarter interim statement 2019 and provide an outlook for 2019.

When major depressive disorder (MDD) does not respond to at least two different types of antidepressant treatments in a moderate-to-severe depressive episode, it is reclassified as treatment-resistant depression or TRD. South San Francisco-based VistaGen Therapeutics’ AV-101 failed to meet its primary efficacy endpoints for TRD in a Phase II clinical trial.